title: Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy.
abstract: Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.
authors.affiliation: Department of Microbiology, Hospital Universitari de Bellvitge. IDIBELL, Department of Pathology and Experimental Therapeutics, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Josep M
authors.initials: JM
authors.lastname: Sierra
authors.forename: Mariana
authors.initials: M
authors.lastname: Camoez
authors.forename: Fe
authors.initials: F
authors.lastname: Tubau
authors.forename: Oriol
authors.initials: O
authors.lastname: Gasch
authors.forename: Miquel
authors.initials: M
authors.lastname: Pujol
authors.forename: Rogelio
authors.initials: R
authors.lastname: Martin
authors.forename: M Angeles
authors.initials: MA
authors.lastname: Domínguez
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000378:metabolism*; D024901:Drug Resistance, Multiple, Bacterial; D006761:Hospitals; D006801:Humans; D000069349:Linezolid; D008297:Male; D008712:Methicillin / Q000627:therapeutic use; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification* / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000627:therapeutic use*; D013030:Spain; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; C539943:CFR protein, Staphylococcus aureus; D023303:Oxazolidinones; D000069349:Linezolid; D008712:Methicillin
references.citation: Antimicrob Agents Chemother. 2008 Apr;52(4):1570-2
references.pmid: 18212098
references.citation: Int J Antimicrob Agents. 2004 Feb;23(2):113-9
references.pmid: 15013035
references.citation: J Clin Microbiol. 2000 Mar;38(3):1008-15
references.pmid: 10698988
references.citation: J Antimicrob Chemother. 2003 May;51 Suppl 2:ii9-16
references.pmid: 12730138
references.citation: Antimicrob Agents Chemother. 2006 Apr;50(4):1156-63
references.pmid: 16569824
references.citation: Future Microbiol. 2011 Aug;6(8):925-31
references.pmid: 21861622
references.citation: Antimicrob Agents Chemother. 2009 Dec;53(12):5275-8
references.pmid: 19805557
references.citation: PLoS Pathog. 2010 Jun 10;6(6):e1000944
references.pmid: 20548948
references.citation: Clin Infect Dis. 2010 Mar 15;50(6):821-5
references.pmid: 20144045
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3374-7
references.pmid: 17576837
references.citation: J Clin Microbiol. 2008 Mar;46(3):892-6
references.pmid: 18174304
references.citation: Antimicrob Agents Chemother. 2012 Apr;56(4):2139-42
references.pmid: 22214776
references.citation: Appl Environ Microbiol. 2003 Jan;69(1):18-23
references.pmid: 12513972
references.citation: Diagn Microbiol Infect Dis. 2008 Dec;62(4):416-26
references.pmid: 19022153
references.citation: Antimicrob Agents Chemother. 2010 Dec;54(12):4978-84
references.pmid: 20921317